Clinical Research Directory
Browse clinical research sites, groups, and studies.
Growth Hormone for the Treatment of Gastroparesis
Sponsor: Mayo Clinic
Summary
The purpose of this study is to determine whether treatment with Growth Hormone results in symptomatic improvement in patients with gastroparesis.
Official title: Low-dose Growth Hormone for the Treatment of Gastroparesis
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2024-10-22
Completion Date
2027-12
Last Updated
2026-02-10
Healthy Volunteers
No
Conditions
Interventions
Growth Hormone
Subjects will receive growth hormone, Sogroya (Somapacitan-beco injections) via weekly injections for 12 weeks. For males, the fixed dose will be 0.2 mg/day, 1.5 mg per week For females, the fixed dose will be 0.3 mg/day, 2.1 mg per week
Locations (2)
Mayo Clinic
Phoenix, Arizona, United States
Mayo Clinic in Arizona
Scottsdale, Arizona, United States